Page 103 - MEMORIA ANUAL 2019 SEHH-FEHH
P. 103

 MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
– Sánchez-Guijo F, Matarraz S, Plata E, Sagüés M, Cortes M, Preloznik Zupan I, Crugno- la M, Caocci G, Oakervee H, Gedde-Dahl T, Warzocha K, Jedrzejczak WW, Kyrcz-Krze- mien S, Kiani A, Supekar S, Ferreira AR, Shah S, Steegmann JL, Baccarani M. Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Pa- tients with Chronic Myeloid Leukemia. Blood. 2019;134(Supplement_1):4160.
– Sánchez R, Ayala R, Carreño Gómez-Tarragona G, Espino MJ, Cuevas B, Vanegas R, Casado Montero LF, García-Ormeña N, Hernández JA, Bravo P, Seri C, Anguita E, Barragán E, Ferrer Marín F, Monteagudo MD, Sánchez-Calero J, Sevilla J, Ruiz E, Villalón L, Herráez MM, Riaza R, Magro E, Steegmann JL, García Gutiérrez V, Martínez-López J. Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leu- kemia Patients. Blood. 2019;134(Supplement_1):5368.
– García Gutiérrez V, Casado LF, Ayala R, Sánchez-Guijo F, Hernández Boluda JC, Gómez Casares MT, Xicoy B, Maestro B, Steegmann JL, García de Diego A. Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study). Blood. 2019;134(Supplement_1):5904.
• 24th Congress of European Hematology Association (EHA). Amsterdam, June 13-16, 2019:
– Casado Montero LF, García-Ormeña N, García-Gutiérrez JV, Giraldo P, Pérez-En- cinas M, De Paz R, Ayala R, Bautista G, Osorio S, Requena MJ, Palomera L, Pe- ñarrubia MJ, Calle C, Hernádez-Rivas JA, Mba C, Steegmann JL. Analysis of the influence of age on major molecular response, deep molecular response and survival outcomes in chronic myeloid leukemia (CML) patients treated with ty- rosine kinase inhibitors (TKIS). Abstract: PF419. Type: Poster Presentation.
– García-Gutiérrez V, Hernández-Boluda JC, Moiraghi B, Szczepanek E, Sacha T, Pavlovsky C, Grzybowska-Izydorczyk O, Correa J, Pérez López R, Patkowska E, Góra-Tybor J, Novo García A, Osorio Prendes S, Vallansot R, Ramírez Payer A, Wa- silewska E, Piris Villaespesa M, Boque Genovard C, Pérez Encinas M, Jiménez Ve- lasco A, Sánchez-Guijo F, Romo Collada MA, Gómez Casares MT, Ortí Pascual G, Durán MS, Portero A, Mata MI, Noya MS, Caballero G, García, Robles de Castro D,
 GRUPO ESPAñOL DE LEUCEMIA MIELOIDE CRóNICA (GELMC)
103
 























































































   101   102   103   104   105